Pharmacy managers inflated drug prices by $7.3 billion

FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
FTC: Pharmacy benefit managers inflated drug prices by $7.3B
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies,
FTC report finds pharmacy benefit managers hiked prices of generic drugs
A new report by the Federal Trade Commission says pharmacy benefit management companies are driving up your out-of-pocket costs for prescription drugs.
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of prescription drugs.
Pharmacy benefit managers have become too powerful
Pharmacy benefit managers make decisions about medication access that aren’t always based on the best interests of patients.
Pharmacy benefit managers marked up drug prices by $7.3B, new reports finds
A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.
Illinois lawmaker seeks more oversight of pharmacy benefit managers, with new bill
The bill is similar to Pennsylvania's new law and would curb PBMs by setting rules for rebates, audits and specialty drug designation.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
PBMs Generated Billions in Drug Markups, FTC Says
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
FTC Launches Inquiry of Single-Family Rental Home 'Mega Investors,' Issues PBM Report
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
pharmaphorum19h
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Will Congress get another shot at PBM reform?
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Congress missed a chance at PBM reforms.